Next Generation Sequencing Market Size Worth $11.7 Billion By 2028: Grand View Research, Inc. to reach USD 11.7 billion by 2028 registering a CAGR of 14.4%, according to a new report by Grand View Research, Inc. As researchers are continuously unlocking the genetic diversity, the development of targeted therapies is on the rise. These therapies are targeted towards narrow populations of patients that have specific or rare genomic biomarkers. Therefore, this is expected to increase the utilization of next generation sequencing (NGS) technology for targeted therapies. Key suggestions from the report: The oncology application segment accounted for the largest revenue share in 2020 and will retain its dominance throughout the forecast period due to the development and launch of targeted gene panels for oncology